Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB1 | P08183 | 13/20 | 0.59 |
| ▸ | ABCC1 | P33527 | 9/20 | 0.57 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6080688 | 1.00 | ABCB1 (0.59) | ABCB1ABCC1KCNMA1NPC1RAB9A | |
| SCHEMBL6587509 | 0.88 | ABCC1 (0.59) | ABCB1ABCC1KCNMA1NPC1RAB9A | |
| SCHEMBL6080754 | 0.85 | KMT2A (0.56) | KCNMA1NPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL6079738 | 0.84 | ALDH1A1 (0.62) | KCNMA1NPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL6080567 | 0.83 | APP (0.54) | KCNMA1NPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL6081086 | 0.83 | ABCB1 (0.52) | ABCB1ABCC1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL6080575 | 0.83 | APP (0.54) | KCNMA1NPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL6080610 | 0.83 | ABCB1 (0.52) | ABCB1ABCC1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL22439814 | 0.81 | ABCB1 (0.68) | ABCB1ABCC1KCNMA1NPC1RAB9A | |
| SCHEMBL6080675 | 0.81 | PKM (0.56) | NPC1RAB9ASMN1; SMN2MAPTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060183909-A1 | Compositions derived from quinoline and quinoxaline, preparation and use thereof | NEURO3D (FR) | 2006-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060183909-A1 | Compositions derived from quinoline and quinoxaline, preparation and use thereof | NQO1, NQO2, RECQL | ABCB1 405/4885ABCC1 346/4885KCNMA1 790/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.